To use all site features Login or Create a User Account

Search eNews

From
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 2005 2006 2007 2008 2009 2010

To
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 2005 2006 2007 2008 2009 2010

eNews from Friday, February 5, 2010

Glyceollins From Soy May Help Prevent, Treat Tumor Growth: Tulane Study

Pharma Investments, Ventures & Law Weekly -- February 14, 2010 -- A new study, 'Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy,' is now available. According to recent research from the United States, "Glyceollins, a group of novel phytoalexins isolated from activated soy, have recently been demonstrated to be novel antiestrogens that bind to the estrogen receptor (ER) and inhibit estrogen-induced tumor progression. Our previous publications have focused specifically on inhibition of tumor formation and growth by the glyceollin mixture, which contains three glyceollin isomers (I, II, and III)."

"Here, we show the glyceollin mixture is also effective as a potential antiestrogenic, therapeutic agent that prevents estrogen-stimulated tumorigenesis and displays a differential pattern of gene expression from tamoxifen. By isolating the individual glyceollin isomers (I, II, and III), we have identified the active antiestrogenic component by using competition binding assays with human ERalpha and in an estrogen-responsive element-based luciferase reporter assay. We identified glyceollin I as the active component of the combined glyceollin mixture. Ligand-receptor modeling (docking) of glyceollin I, II, and III within the ERalpha ligand binding cavity demonstrates a unique type II antiestrogenic confirmation adopted by glyceollin I but not isomers II and III. We further compared the effects of glyceollin I to the antiestrogens, 4-hydroxytamoxifen and ICI 182,780 (fulvestrant), in MCF-7 breast cancer cells and BG-1 ovarian cancer cells on 17beta-estradiol-stimulated expression of progesterone receptor and stromal derived factor-1alpha. Our results establish a novel inhibition of ER-mediated gene expression and cell proliferation/survival," wrote M.C. Zimmermann and colleagues, Tulane University, Department of Pharmacology (see also Pharmacology).

The researchers concluded: "Glyceollin I may represent an important component of a phytoalexin-enriched food (activated) diet in terms of chemoprevention as well as a novel therapeutic agent for hormone-dependent tumors."

Zimmermann and colleagues published their study in the Journal of Pharmacology and Experimental Therapeutics (Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. Journal of Pharmacology and Experimental Therapeutics, 2010;332(1):35-45).

For additional information, contact M.C. Zimmermann, Tulane University, Dept. of Pharmacology, New Orleans, Louisiana 70112 USA.

(c) 2010 Pharma Investments, Ventures & Law Weekly via NewsRx.com

Copyright notice
This is a news service of NewsEdge Corporation ©2010. This content is for your personal use only, subject to Terms and Conditions. No redistribution allowed.

About Soyatech  |   Advertising Services  |   Privacy Policy  |   Legal Notices  |   Contact Soyatech  |   Site Map